Buy Rating Affirmed: Butterfly Network's Growth and Innovation With IQ+ Bladder Launch
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Butterfly Network (BFLY) and Deciphera Pharmaceuticals (DCPH)
Butterfly Network (BFLY) Receives a Buy From Oppenheimer
Buy Rating Justified: Butterfly Network's Growth Strategy and Innovative Product Roadmap
Butterfly Network (BFLY) Receives a Buy From Oppenheimer
Analysts Have Conflicting Sentiments on These Healthcare Companies: Butterfly Network (BFLY) and Codexis (CDXS)
Oppenheimer Keeps Their Buy Rating on Butterfly Network (BFLY)
Analysts' Top Healthcare Picks: Asensus Surgical (ASXC), Butterfly Network (BFLY)
Butterfly Network's Recent Developments and Financial Performance: A Buy Rating Justified
Oppenheimer Reaffirms Their Buy Rating on Butterfly Network (BFLY)
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Butterfly Network (BFLY) and Kura Oncology (KURA)
Butterfly Network's Expanding Horizons: A Buy Rating Supported by POCUS Market Reach, Ultrasound-on-a-Chip Dominance, and Potential Growth in Home Care and BCI Technologies
B. Riley Trims Butterfly Network's Price Target to $4 From $5 to Reflect Lowered 2023 Outlook, Keeps Buy Rating
B.Riley Financial Reaffirms Their Buy Rating on Butterfly Network (BFLY)
B. Riley Trims Butterfly Network's Price Target to $5 From $7.50 After Slight Q1 Miss, Keeps Buy Rating
B.Riley Financial Reaffirms Their Buy Rating on Butterfly Network (BFLY)
Butterfly Network (BFLY) Receives a Buy From B.Riley Financial
B.Riley Financial Remains a Buy on Butterfly Network (BFLY)
UBS Initiates Coverage on Butterfly Network With Neutral Rating, $2.25 Price Target
UBS Initiates Coverage On Butterfly Network With Neutral Rating, Announces Price Target of $2.25